What does a gene therapy biotech like Bluebird Bio (NASDAQ: BLUE) have to do with a cryptocurrency like Shiba Inu (CRYPTO: SHIB), one of the hottest meme coins of yesteryear? If you said "they're both risky investments," you're correct.

Most well-diversified portfolios should have an allocation to high-risk, high-reward investments, because finding even one that delivers a disproportionately large gain can be enormously beneficial. But which of these two risky investments is the better play? Let's examine Bluebird first.

At a glance, it looks like Bluebird Bio and its shareholders should be sitting pretty. It has three gene therapies on the market, all of which were approved in the past year and a half. Its drug Lyfgenia, a near-curative medicine for sickle cell disease (SCD), was just approved for sale on Dec. 8.

Continue reading

Source Fool.com